Skip to main content
. 2021 Apr 26;12:628651. doi: 10.3389/fphar.2021.628651

FIGURE 4.

FIGURE 4

Immunohistochemistry (IHC) and western blot assays of HPL-treated samples. (A) IHC revealed a disturbed morphology of uterine and renal tissues (DAB staining, scale bar, 200 µm). (B) The IHC average optional density (AOD) ratio. (C) Representative images of ERα, ERβ, Ggt1, and Anpep levels detected using western blotting. (D) Representative quantitation of ERα, ERβ, Ggt1, and Anpep levels detected using western blotting. (E) qRT-PCR analysis of renal levels of the Ggt1 and Anpep mRNAs. The results of the statistical analysis are presented in bar charts (mean ± s. e.m.). HPL therapy dosage: HPL-H, 300 mg/kg/d; HPL-L, 80 mg/kg/d. *p < 0.05, **p < 0.005, and ***p < 0.0005 compared with control rats; #p < 0.05, ##p < 0.005, and ###p < 0.0005 compared with OVX rats. NS, not significant.